Kartos Therapeutics

Redwood City, CA · Founded 2018 · Privately Held (backing)

Operator of a biopharmaceutical company intended to offer investigational inhibitors for cancer treatment. Kartos Therapeutics is based in Redwood City, CA and was founded in 2018. It is valued at about $650 million as of Oct 2026, set by institutional fund marks. It has raised $265 million.

PMV mark · valuation
$650.0M
Oct 2026
Priced at
—
Total raised
$265.0M
Last round
—
What is Kartos Therapeutics worth?
$650.0MPrivateMarketView mark · Oct 2026

Reported valuation; nothing comparable since.

Pro
The prices on Kartos Therapeutics
  • ·11 fund marks: filer, period, implied $/share
Pro · $99 a month
List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Kartos Therapeutics funding history

No rounds on record

No funding rounds for Kartos Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Kartos Therapeutics valuation

Kartos Therapeutics is valued at approximately $650 million as of Oct 2026. The figure is set by institutional fund marks.

Recent activity

In the last 90 days, Kartos Therapeutics's record added 5 institutional fund marks (latest period Jul 2026).

Institutional holders and vehicles

1 SEC-registered fund reported 11 fair-value marks on Kartos Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

How Kartos Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Kartos Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →

Frequently asked about Kartos Therapeutics

What is Kartos Therapeutics worth?
Kartos Therapeutics is valued at $650.0M as of Oct 2026. Reported valuation; nothing comparable since.
How much has Kartos Therapeutics raised?
Kartos Therapeutics has raised $265.0M in total funding across its recorded rounds.